PURPOSE: To determine whether activation of the ERK pathway by EGF leads to rat and human goblet cell proliferation. METHODS: The conjunctiva was removed from male Sprague-Dawley rats. Human conjunctiva was removed during ocular surgery. The tissue was minced and goblet cells were grown. The cells were stimulated with EGF (10(-7) M) for 1 and 5 minutes and Western blot analysis was performed with an antibody against phosphorylated EGFR, to measure the activation of the EGF receptor (EGFR). The cells were incubated with EGF (10(-7) M) for 24 hours, and cell proliferation was measured by WST-8. Inhibitors were added either 20 minutes before EGF or 2 hours after. The cells were stimulated with EGF (10(-7) M) for 1 minute to 24 hours. The number of cells expressing phosphorylated ERK (pERK) in the nucleus and Ki-67 was determined by immunofluorescence. RESULTS: EGF increased the activation of EGFR in rat conjunctival goblet cells. EGF-stimulated proliferation was inhibited by the EGFR inhibitor AG1478 and the MEK inhibitor U0126 in rat and human cultured goblet cells. EGF caused the translocation of pERK to the nucleus in a biphasic manner. Inhibition of the second peak with U0126 prevented proliferation. EGF-stimulated goblet cells progressed through the cell cycle expressing pERK in the nucleus. CONCLUSIONS: EGF stimulated human and rat conjunctival goblet cell proliferation by activating the EGFR. EGFR stimulated ERK causing its biphasic translocation to the nucleus. The second peak response is responsible for cell proliferation, but the role of the first peak is not known.
PURPOSE: To determine whether activation of the ERK pathway by EGF leads to rat and human goblet cell proliferation. METHODS: The conjunctiva was removed from male Sprague-Dawley rats. Human conjunctiva was removed during ocular surgery. The tissue was minced and goblet cells were grown. The cells were stimulated with EGF (10(-7) M) for 1 and 5 minutes and Western blot analysis was performed with an antibody against phosphorylated EGFR, to measure the activation of the EGF receptor (EGFR). The cells were incubated with EGF (10(-7) M) for 24 hours, and cell proliferation was measured by WST-8. Inhibitors were added either 20 minutes before EGF or 2 hours after. The cells were stimulated with EGF (10(-7) M) for 1 minute to 24 hours. The number of cells expressing phosphorylated ERK (pERK) in the nucleus and Ki-67 was determined by immunofluorescence. RESULTS: EGF increased the activation of EGFR in rat conjunctival goblet cells. EGF-stimulated proliferation was inhibited by the EGFR inhibitor AG1478 and the MEK inhibitor U0126 in rat and human cultured goblet cells. EGF caused the translocation of pERK to the nucleus in a biphasic manner. Inhibition of the second peak with U0126 prevented proliferation. EGF-stimulated goblet cells progressed through the cell cycle expressing pERK in the nucleus. CONCLUSIONS: EGF stimulated human and rat conjunctival goblet cell proliferation by activating the EGFR. EGFR stimulated ERK causing its biphasic translocation to the nucleus. The second peak response is responsible for cell proliferation, but the role of the first peak is not known.
Authors: H M Lee; K Takeyama; K Dabbagh; J A Lausier; I F Ueki; J A Nadel Journal: Am J Physiol Lung Cell Mol Physiol Date: 2000-01 Impact factor: 5.464
Authors: Isao Ota; Driss Zoukhri; Robin R Hodges; José D Rios; Vanja Tepavcevic; Isabelle Raddassi; Li Li Chen; Darlene A Dartt Journal: Am J Physiol Cell Physiol Date: 2002-09-11 Impact factor: 4.249
Authors: Jian Gu; Lili Chen; Marie A Shatos; J David Rios; Abha Gulati; Robin R Hodges; Darlene A Dartt Journal: Exp Eye Res Date: 2007-11-17 Impact factor: 3.467
Authors: Darlene A Dartt; Robin R Hodges; Dayu Li; Marie A Shatos; Kameran Lashkari; Charles N Serhan Journal: J Immunol Date: 2011-02-28 Impact factor: 5.422
Authors: Robin R Hodges; Jeffrey A Bair; Richard B Carozza; Dayu Li; Marie A Shatos; Darlene A Dartt Journal: Exp Eye Res Date: 2012-09-04 Impact factor: 3.467
Authors: Marie A Shatos; Robin R Hodges; Jeffrey A Bair; Kameran Lashkari; Darlene A Dartt Journal: Invest Ophthalmol Vis Sci Date: 2008-12-13 Impact factor: 4.799
Authors: Marie A Shatos; Robin R Hodges; Yoshia Oshi; Jeffrey A Bair; Driss Zoukhri; Claire Kublin; Kameran Lashkari; Darlene A Dartt Journal: Invest Ophthalmol Vis Sci Date: 2008-09-29 Impact factor: 4.799